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Figure S1. ChAd-SARS-CoV-2-S vaccine induces neutralizing antibodies as measured by 
FRNT. Related to Figure 1. Five-week old female BALB/c mice were immunized via IN or IM 
route with a single 1010, 109, or 108 dose of ChAd-SARS-CoV-2-S. Serum samples from ChAd-
SARS-CoV-2-S vaccinated mice were collected at days 100 (A) or 200 (B) after immunization 
and assayed for neutralizing activity by FRNT. Serum neutralization curves corresponding to 
individual mice are shown for the indicated vaccines (n = 6-14 per group). Each point represents 





Figure S2. ChAd-SARS-CoV-2-S vaccine induces neutralizing antibodies as measured by 
FRNT. Related to Figure 4. Five-week-old K18-hACE2 female mice were immunized with 109 vp 
ChAd-control or ChAd-SARS-CoV-2-S via an IN route. Serum samples were collected at six 
weeks (A) or nine months (B) after immunization and assayed for neutralizing activity against 
WA1/2020, Wash-B.1.351, Wash-B.1.1.28, or B.1.617.1 by FRNT. Serum neutralization curves 
corresponding to individual mice are shown for the indicated vaccines (n = 7-20 per group). Each 
point represents the mean of two technical replicates. 
	
